Anti-anxiety, antiallergic or pancreatic medicines can be effective in fighting coronavirus. More and more specifics are proving effective in the treatment of Covid-19.
Not only is Wuhan coronavirus dangerous, but also other dangerous coronaviruses. In addition to SARS-CoV-2, there are seven known single-stranded RNA viruses that infect humans. Four are responsible for 30 percent. cold cases. Two proved to be the perpetrators of dangerous epidemics – SARS-CoV-1 (2002–2003), and MERS-CoV, which causes Middle Eastern respiratory distress syndrome MERS, which kills approximately 35 percent. cases.
The number of patients with SARS and MERS was small compared to COVID-19 , which is spread due to asymptomatic carriers, long latency periods and high infectivity.
Remdesivir , whose experimental use has been agreed by the US Food and Drug Administration The FDA only works when the virus is multiplying intensively. This may alleviate the course of the disease, but does not guarantee a cure.
Research is ongoing on the properties of various drugs – from anxiolytic to antiallergic. During laboratory tests on monkey cell cultures, antipsychotic haloperidol, antidepressant syramazine, antihistamine clemastine and cloperastine, and experimental anti-tumor zotatifin gave promising results . None of these have been tried in patients with COVID-19.
Clinical observations, however, indicated famotidine for heartburn , which inhibits gastric acid secretion. Patients who took famotidine and then contracted COVID-19 had more than twice the chance of survival. However, only 84 patients taking famotidine were included in the study, and the results of the larger study will be known in a few months.
The multiplication of the virus can also interfere with the female hormone progesterone , which could partly explain why men die more often from COVID-19.
Adjunctive therapy is the administration of plasma antibodies to people who have recovered from COVID-19. Antibodies can help remove coronavirus as well as help you recover faster. The method is used at the Central Clinical Hospital of the Ministry of Interior and Administration in Warsaw. Since the outbreak of the epidemic, doctors from the MSWiA transformed into a unified hospital have also used intravenous tocilizumab – an antibody that blocks the development of inflammation – interleukin 6. It has been used to treat rheumatoid arthritis.
Given to patients with so-called cytokine storm syndrome (excessive response of the immune system) reduces the severity of clinical symptoms and reduces the time of dependence on the ventilator.